A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

November 6, 2013

Long-Acting HIV Drugs Could Extend Lives of Low Adherers

The current crop of long-acting antiretrovirals (ARVs) in development, which aim to require only monthly or quarterly dosing, could improve life expectancy among people with HIV, especially those with low adherence to daily regimens, HIVandHepatitis.com reports. Investigators used a mathematical model to project the various impacts of long-acting ARVs in three scenarios: as the first-line therapy among treatment-naive people with HIV; as a second-line therapy for those who had failed their first-line treatment; and for those who have failed multiple regimens based on non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs). The investigators presented their findings at the IDWeek 2013 conference in San Francisco.

The researchers found that long-acting ARVs would increase overall life expectancy by 0.5 to 0.6 years when compared with standard ARVs. Among those with low adherence to standard ARVs, treatment with long-acting drugs by comparison would increase life expectancy by two to three years.

Long-acting treatment was only cost effective among those who had failed multiple regimens, at $86,000 per quality adjusted life year. Giving the long-acting therapies to those with lowered adherence, however, increased its cost effectiveness in comparison with the cost-effectiveness for those with high adherence.

To read the IDWeek abstract, click here.

To read the HIVandHepatitis story, click here.

Search: Long-acting antiretrovirals, adherence, life expectancy, quality adjusted life years, cost-effectiveness, IDWeek.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    dhsd777
    san diego
    California


    usuallyhappy
    Palm Springs
    California


    sefarady
    New York
    California


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.